The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.
Consenting patients with suspected or verified SARS-COV-2 infection, COVID-19, will undergo daily blood, urine and sputum sampling during their stay in intensive care. Data on organ dysfunction will be collected through the electronic patient journal and electronic patient data management system. The collected samples will be analysed for a panel of potential biomarkers that will be correlated to organ dysfunction and clinical outcome.
Study Type
OBSERVATIONAL
Enrollment
380
Uppsala University Hospital
Uppsala, Uppsala County, Sweden
Acute Kidney Injury
KDIGO AKI score
Time frame: During Intensive Care, an estimated average of 10 days.
ARDS
Acute Respiratory Distress Syndrome yes/no
Time frame: During intensive care, an estimated average of 10 days.
30 day mortality
Death within 30 days of ICU admission
Time frame: 30 days
1 year mortality
Death within 1 year of ICU admission
Time frame: 1 year
Chronic Kidney Disease
Development of Chronic Kidney Disease
Time frame: 60 days and 1 year after ICU admission
SOFA-score
Sequential Organ Failure Score as a continuous variable
Time frame: During Intensive Care, an estimated average of 10 days.
Thromboembolic events
Occurence of thrombosis and/or embolous
Time frame: During intensive care
ICUAW
Intensive care acquired weakness
Time frame: During intensive care or after intensive care
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.